The 2000 Canadian recommendations for the management of hypertension: Part two - Diagnosis and assessment of people with high blood pressure

Canadian Journal of Cardiology

Volumn 17, Issue 12, 2001, Pages 1249-1263

  Zarnke, Kelly B ^a   Levine, Mitchell ^a   McAlister, Finlay A ^a   Campbell, Norman R C ^a   Myers, Martin G ^a   McKay, Donald W ^a   Bolli, Peter ^a   Honos, George ^a   Lebel, Marcel ^a   Mann, Karen ^a   Wilson, Thomas W ^a   Abbott, Carl ^a   Tobe, Sheldon ^a   Burgess, Ellen ^a   Rabkin, Simon ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Blood pressure; Diagnosis; Hypertension; Risk factors

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANABENZ; MONOAMINE OXIDASE INHIBITOR; TYRAMINE;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD DRUG INTERACTION; HEALTH CARE PLANNING; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LABORATORY TEST; LIFESTYLE; MEDLINE; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; REVIEW; RISK FACTOR; TARGET ORGAN;

ADRENAL GLAND NEOPLASMS; ADULT; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CANADA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETIC NEPHROPATHIES; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; LABORATORY TECHNIQUES AND PROCEDURES; OFFICE VISITS; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; RISK FACTORS; SELF CARE;

EID: 0035716230     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. 1999 Canadian recommendations for the management of hypertension
2. A novel process for updating recommendations for managing hypertension: Rationale and methods
3. The 2000 Canadian recommendations for the management of hypertension: Part 1 - Therapy
4. Arm position is important for blood pressure measurement
5. The effect of crossing legs on blood pressure: A randomized single-blind cross-over study
6. Measurement of blood pressure: An evidence based review
7. Consequences of banning mercury and the cuff controversy
8. Replacing the mercury sphygmomanometer. Requires clinicians to demand better automated devices
9. A comparison of the British Hypertension Society and Association for the Advancement of Medical Instrumentation protocols for validating blood pressure measuring devices: Can the two be reconciled?
10. An outline of the revised British Hypertension Society protocol for the evaluation of blood pressure measuring devices
11. Blood pressure measuring devices: Recommendations of the European Society of Hypertension
12. Predictive values of routine blood pressure measurements in screening for hypertension
13. Difficulties in diagnosing hypertension: Implications and alternatives
14. How many measurements are necessary in diagnosing mild to moderate hypertension?
15. Prediction of coronary heart disease using risk factor categories
16. The Prospective Cardiovascular Muenster (PROCAM) study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease
17. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs
18. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association
19. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests
20. Recent progress in the diagnosis, prognostic evaluation and treatment of pheochromocytomas
21. The urinary metanephrine-to-creatinine ratio for the diagnosis of pheochromocytoma
22. Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice
23. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma
24. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2
25. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: A randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group
26. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group
27. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group
28. Long-term outcome with surgical treatment of renovascular hypertension
29. Percutaneous transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia
30. Percutaneous transluminal angioplasty: The treatment of choice for renovascular hypertension due to fibromuscular dysplasia
31. A clinical prediction rule for renal artery stenosis
32. Possible familial origin of multifocal renal artery fibromuscular dysplasia
33. Renal hemodynamics in essential and renovascular hypertension. Influence of captopril
34. Acute renal failure after the use of angiotensin-converting-enzyme inhibitors in patients without renal artery stenosis
35. Comparison between the effects of amlodipine and lisinopril on proteinuria in nondiabetic renal failure: A double-blind, randomized prospective study
36. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria
37. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical revascularisation
38. Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization. The Yale Vascular Center experience
39. Simplified captopril renography in diagnosis and treatment of renal artery stenosis
40. Captopril renography in the diagnosis of renal artery stenosis: Accuracy and limitations
41. Captopril radionuclide test in renovascular hypertension: A European multicentre study. European Multicentre Study Group
42. The place of renal scintigraphy in the diagnosis of renal artery stenosis. Fifteen years of clinical experience
43. Prospective study of simultaneous orthoiodohippurate and diethylenetriaminepentaacetic acid captopril renography. The Einstein/Cornell Collaborative Hypertension Group
44. Imaging of renovascular hypertension: Respective values of renal scintigraphy, renal Doppler US, and MR angiography
45. Diagnosis of renal artery stenosis and renovascular hypertension
46. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis
47. Renovascular hypertension with low-to-normal plasma renin: Clinical and angiographic features
48. Self-recording of blood pressure in the management of hypertension
49. Improvement of medication compliance in uncontrolled hypertension
50. Effects of intensified antihypertensive treatment in diabetic nephropathy: Mortality and morbidity results of a prospective controlled 10-year study
51. Intensified antihypertensive therapy is associated with improved survival in type 1 diabetic patients with nephropathy
52. Proposal of reference values for home blood pressure measurement: Prognostic criteria based on a prospective observation of the general population in Ohasama, Japan
53. Reference values for self-recorded blood pressure: A meta-analysis of summary data
54. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: A population-based observation in Ohasama, Japan
55. Predictive value of home blood pressure measurement in relation to stroke morbidity: A population-based pilot study in Ohasama, Japan
56. White coat effect detected using self-monitoring of blood pressure at home: Comparison with ambulatory blood pressure
57. Self-measurement of blood pressure: Recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control
58. Self-measurement of blood pressure: Issues related to the training of patients. Canadian Coalition for High Blood Pressure Prevention and Control
59. Self-measurement of blood pressure: Assessment of equipment. Canadian Coalition for High Blood Pressure Prevention and Control
60. Blood pressure self-measurement in the elderly: Differences between automatic and semi-automatic systems
61. Self-measurement of blood pressure at home: The potential for reporting bias
62. Reliability of reporting self-measured blood pressure values by hypertensive patients
63. Reliability of patients measuring blood pressure at home: Prospective observational study
64. Reliability of self-reported blood pressure measurements
65. Home blood pressure measurement: Reliability of patients' reports, acceptability and comparison with office and ambulatory blood pressure
66. Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the British hypertension society
67. Reference values for 24-hour ambulatory blood pressure monitoring based on a prognostic criterion: The Ohasama Study
68. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension
69. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators
70. Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure
71. Attenuation of the "white-coat effect" by antihypertensive treatment and regression of target organ damage
72. Physical activity level is an independent predictor of the diurnal variation in blood pressure
73. Ambulatory physical activity as a determinant of diurnal blood pressure variation
74. Ambulatory pulse pressure: A potent predictor of total cardiovascular risk in hypertension
75. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
76. Should echocardiography be performed to assess effects of antihypertensive therapy? Test-retest reliability of echocardiography for measurement of left ventricular mass and function
77. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement
78. Effect of regression to the mean in serial echo-cardiographic measurements of left ventricular mass. Quantification and clinical implications
79. The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study: Rationale, design, and methods. The LIFE Study Group
80. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: From the Investigators of Consensus on Diastolic Dysfunction by Echocardiography
81. Guidelines from the Canadian Cardiovascular Society and the Canadian Hypertension Society on the echocardiographic determination of left ventricular mass. Task Force of the Echocardiography Section
82. The 2000 Canadian Hypertension Recommendations: A summary. The Canadian Hypertension Recommendations Working Group
83. Resume des recommendations canadiennes de l'an 2000 sur l'hypertension. Le groupe de travail sur les recommendations canadiennes sur l'hypertension